liver-2018-posters-accepted-abstracts

4 / 20

Page 42
Notes:
alliedacademies
Journal of Gastroenterology and Digestive Diseases | Volume 3
May 25-26, 2018 | New York, USA
World Liver Conference 2018
The aim of the clinical trial was to determine
hepatoprotective effect of the new Lonal drug in patient
with drug induced steatosis. The research was considered
such as clinical trial guideline for new drug issued by the
World Health Organization’s "Good Clinical Practice” based
on permission given by Biomedical Ethical Community of the
Health Ministry of Mongolia approved diagnosis patient with
drug induced steatosis. The research design is Randomized
Placebo-Controlled, Double Blind Clinical Trial. Lonal drug
significant decreases hepatocellular and cholestatic injury.
The Lonal drug was taken during 21 days and comparing
the some results of metabolic syndrome before and after
treatment, reduces TG (p=0.03). The participants have
taken the fibroscan and liver biopsy. That was compared to
determine before and after treatment such as steatosis and
fibrosis degree of participants liver. Before treatment degree
of steatosis was S3, after treatment it was dropped S2 (p
<0.05). And before treatment, such as fibrosis degree F1-
2, after treatment it was decreased F0 (p<0.05). New Lonal
drug is reducing hepatocellular injury, cholestatic injury and
some criteria of the metabolic syndrome in patient drug
induced steatosis. Also new Lonal drug reduces activation of
inflammation, decreases the degree of liver steatosis fibrosis
validated by liver biopsy and fibroscan.
e:
The result of clinical trial for the new lonal drug for hepatoprotective effect in patient with drug
induced steatosis: A randomized placebo-controlled double blind clinical trail
Ariunaa Zundui1, Sarnai T S 2, Erdenetsogt D2, Badamsuren D3, 2,Badamjaw S 2 and Enkhbaatar D 1
1Treatment, Research and Production Company of the Mong-Em, Mongolia
2Mongolian National University of Medical Science, Mongolia
33rd State Hospital named by Shastin P N, Mongolia